Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11014966 | 0.70 | — | — | |
| SCHEMBL26568239 | 0.70 | POLB (0.35) | POLBPIK3CDHDAC2 | |
| SCHEMBL19484938 | 0.70 | MEN1 (0.43) | POLBEPHX1MEN1KMT2A | |
| SCHEMBL9910982 | 0.69 | EPHX1 (0.36) | POLBEPHX1MEN1KMT2A | |
| SCHEMBL11718113 | 0.69 | — | — | |
| SCHEMBL13884523 | 0.69 | CA12 (0.39) | EPHX1MEN1KMT2A | |
| SCHEMBL17663622 | 0.67 | SIGMAR1 (0.38) | CTSK | |
| SCHEMBL42259 | 0.66 | — | — | |
| SCHEMBL18594653 | 0.65 | POLB (0.46) | POLBMEN1KMT2APIK3CDHDAC2 | |
| SCHEMBL23084588 | 0.65 | POLB (0.46) | POLBEPHX1MEN1KMT2APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018028365-A1 | DYNAMIC POLYMER WITH HYBRID CROSS-LINKED NETWORK AND APPLICATION THEREOF | 翁秋梅 | 2018-02-15 | — | — | WO | disclosed |
| US-20170301953-A1 | FUNCTIONALIZED SILANES AND ELECTROLYTE COMPOSITIONS AND ELECTROCHEMICAL DEVICES CONTAINING THEM | ORBIA FLUOR & ENERGY MATERIALS USA, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | ASCENDIS PHARMA A/S (DK) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170301953-A1 | FUNCTIONALIZED SILANES AND ELECTROLYTE COMPOSITIONS AND ELECTROCHEMICAL DEVICES CONTAINING THEM | ZYX, HCN4, HCN3 | POLB 1573/4885EPHX1 2906/4885MEN1 1634/4885 |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | PTMS, PGLS, PAM | POLB 3230/4885EPHX1 164/4885MEN1 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.